**FAST FACTS AND CONCEPTS #228**

**TAPENTADOL**

**Rohtesh S Mehta MD, MPH and Robert M Arnold MD**

**Background** Tapentadol is a newly available oral analgesic, approved by the FDA in 2009 for the management of moderate to severe acute pain in adults. This *Fast Fact* reviews its pharmacology and use.

**Pharmacology**

* Tapentadol is a centrally-acting, synthetic, oral mu-opioid receptor agonist which also inhibits norepinephrine and serotonin reuptake within the CNS. It is structurally and pharmacologically similar to tramadol (see *Fast Fact* #290 for more information on tramadol).
* Oral bioavailability ranges from 32% to 42%, with a half-life of 4 ½ hours.
* The drug is metabolized in the liver (97% by Phase-2 conjugation) and excreted in the urine.
* Tapentadol has no known pharmacologically active metabolites, no relevant CYP interactions, and no drug-drug interactions through cytochrome induction or inhibition (1).
* There are no dosing adjustments required in mild-to-moderate renal or hepatic impairment (Child class A or B); it has not been studied in patients with severe hepatic impairment (Child class C).

**Research Data** The FDA approval was based on industry-coordinated, randomized controlled studies conducted in patients with osteoarthritis and after bunionectomy. In these studies 50 mg doses of tapentadol was shown to be non-inferior to 10 mg of oxycodone immediate-release in the treatment of pain, but the incidence of nausea, vomiting, dizziness, and constipation was significantly lower (2,3). In another single-dose study involving patients undergoing molar extraction, tapentadol 200 mg demonstrated improved analgesia but higher sedation than 60 mg of oral morphine (4). Total daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been tested, nor has tapentadol been studied in children. Tapentadol has not been tested in a randomized, controlled fashion for cancer pain nor in palliative care settings; however, prospective observational studies showed it to be well tolerated and effective for opioid naïve (doses 100 mg per day) and opioid tolerant patients (doses 350 to 450 mg per day) with moderate to severe cancer pain (5,6). There are not enough data to comment on whether the drug has a ceiling effect, nor its long-term safety and efficacy (the longest study is a 1 year safety study). It has not been comparatively studied against tramadol.

**Side Effects and Cautions** Tapentadol’s side effect profile is generally similar to opioids: nausea, vomiting, constipation, addiction, respiratory depression, pruritus, dizziness and drowsiness. A pooled analysis of randomized controlled trials suggest that gastro-intestinal side effects are likely milder than other opioids (7). As with tramadol, there is a theoretical increased risk of seizures, as well as serotonin syndrome if given with other serotonergic agents (e.g. antidepressants, drugs with monamine oxidase inhibitory effects). Abuse and addiction are possible as with any opioid agonist. An abstinence syndrome has not yet been described; in one study drug tapering was not required after 90 days of treatment (2).

**Dosing and Cost** Tapentadol is available as 50, 75 and 100 mg immediate-release tablets and 50, 100, 150, 200, and 250 mg extended release tablets. The initial dose is 50-100 mg every 4 hours (although a second dose can be given one hour after the initial dose). The average wholesale pricing for tapentadol is approximately $5 to $7 per immediate release tab and $5 to $15 per extended release tablet. For comparison, tramadol costs $0.07/tab (50 mg), oxycodone costs $0.70 (15 mg tab), and morphine costs $0.18 (15 mg tab).

**Summary** Tapentadol is a novel analgesic, with a 50 mg dose similar in efficacy to 10 mg of oxycodone. Currently its only clearly defined benefit over established opioids is its gentler GI side effect profile. Its cost, potential ceiling effect, safety concerns with drug interactions, and uncertainty about long-term efficacy and safety limit its current application.

**References**

1. Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. *Drug Metab Lett.* 2008; 2(1):67-75. PMID: 19356073.
2. Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. *Curr Med Res Opin*. 2009; 25(5):1095-104. PMID: 19301989.
3. Daniels S, Casson E, Stegmann JU, Oh C, Okamoto A, Rauschkolb C, Upmalis D. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. *Curr Med Res Opin*. 2009; 25(6):1551-61. PMID: 19445652.
4. Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. *Anesth Analg*. 2008; 107(6):2048-55. PMID: 19020157.
5. Mercadante S, Porzio G, et al. Tapentadol in cancer pain management: a prospective open-label study. *Curr Med Res & Opinion* 2012; 28:1775-1779.
6. Mercadante S, Porzio G, et al. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. *Curr Med Res & Opinion* 2014; 30:2063-2068.
7. Etropolski M, Kuperwasser B, et al. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. *Adv Ther* 2014; 31:604-620.

**Author Affiliations:** University of Pittsburgh Medical Center, Pittsburgh, PA.

**Version History:**  Originally published April 2010; copy-edited August 2015 with references #5-7 added and incorporated into the text.

***Fast Facts and Concepts*** are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the [Palliative Care Network of Wisconsin](http://www.mypcnow.org/) (PCNOW) and the Center to Advance Palliative Care ([www.capc.org](http://www.capc.org/)). *Fast Facts and Concepts* are editorially independent of PCNOW and the Center to Advance Palliative Care, and the authors of each individual *Fast Fact* are solely responsible for that *Fast Fact’s* content. The full set of *Fast Facts* are available at [http://www.mypcnow.org/#!fast-facts/cb1h](http://www.mypcnow.org/%23!fast-facts/cb1h) or <http://www.capc.org/fast-facts/> along with contact information, and how to reference *Fast Facts.*

**Copyright:**  All *Fast Facts and Concepts* are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright (<http://creativecommons.org/licenses/by-nc/4.0/>). *Fast Facts* can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a *Fast Fact*, let us know!

**Disclaimer:** *Fast Facts and Concepts* provide educational information for health care professionals. This information is not medical advice. *Fast Facts* are not continually updated, and new safety information may emerge after a *Fast Fact* is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some *Fast Facts* cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.